Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Samsung Biologics has announced a formal plan to acquire the Swiss contract development and manufacturing organization PolyPeptide Group AG. According to reports from Reuters, CNBC, and Bloomberg, the proposed transaction is an all-cash bid valued at $1.8 billion, which TradingView further specifies as 2.7 trillion won. The offer is structured as a tender offer to acquire the company for CHF 44.31 per share. This move marks a significant expansion for Samsung Biologics as it seeks to integrate the Swiss peptide maker into its broader operations to enhance its capabilities in the pharmaceutical sector. Coverage from multiple outlets, including PR Newswire and cbs19news.com, emphasizes that this acquisition is designed to accelerate a multi-modality strategy.

The reports highlight that by acquiring PolyPeptide, Samsung Biologics intends to expand its global network, specifically targeting growth across the United States, Europe, and India. Fierce Pharma describes the move as the company "spreading its wings," while the Korean outlet 조선일보 explicitly links the acquisition of the Swiss CDMO to the production and supply of obesity drugs, positioning the deal within a specific therapeutic market. Contextually, this acquisition reflects a strategic pivot toward diversifying manufacturing modalities. The deal allows Samsung Biologics to leverage PolyPeptide's existing infrastructure and expertise in peptide synthesis. This is particularly relevant given the increasing demand for complex peptides used in modern medicine.

The financial scale of the $1.8 billion deal underscores the company's commitment to scaling its international footprint and moving beyond its current operational constraints to capture more of the global CDMO market through the addition of Swiss-based assets. Market reactions following the announcement have been mixed across different trading platforms. Investing.com reports that PolyPeptide stock surged following the news of the bid, while simultaneously noting that Samsung Biologics stock experienced a slide. Future developments to monitor include the official acceptance of the tender offer at the price of CHF 44.31 per share and the subsequent integration of PolyPeptide's sites in the U.S., Europe, and India into the Samsung Biologics global network as part of its multi-modality strategy.